HD is a terminal neurotoxic disease. The higher dose of PBT2 was needed because, as with AD, PBT2 was on trend to show benefits that seemed to be dose dependent.
I would have thought a tightly monitored trial at a higher dose was warranted to confirm these benefits with neurotoxicity compared to a control group.
Given the demonstrated benefit, FDA orphan status etc. Surely these issues will be resolved, just not today.
GLTAH
HD is a terminal neurotoxic disease. The higher dose of PBT2 was...
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $13.64K | 3.897M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 49 | 57452006 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 125993867 | 29 |
View Market Depth
| Last trade - 10.49am 29/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |